Hoffman, AJ; Nichols, DE. Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. J. Med. Chem., 1 Sep 1985, 28 (9), 1252–1255. 583 kB. https://doi.org/10.1021/jm00147a022
Watts, VJ; Mailman, RB; Lawler, CP; Neve, KA; Nichols, DE. LSD and structural analogs: Pharmacological evaluation at D1 dopamine receptors. Psychopharmacology, 1 Apr 1995, 118 (4), 401–409. 1.4 MB. https://doi.org/10.1007/BF02245940
Brandt, SD; Kavanagh, PV; Westphal, F; Elliott, SP; Wallach, J; Colestock, T; Burrow, TE; Chapman, SJ; Stratford, A; Nichols, DE; Halberstadt, AL. Return of the lysergamides. Part II: Analytical and behavioural characterization of N6-allyl-6-norlysergic acid diethylamide (AL-LAD) and (2′S,4′S)-lysergic acid 2,4-dimethylazetidide (LSZ). Drug Test. Anal., 1 Jan 2017, 9 (1), 38-50. 1.6 MB. https://doi.org/10.1002/dta.1985
Chapman, SJ; Burns, D; Burrow, TE. 1H and 13C NMR spectra of N6-allyl-6-norlysergic acid diethylamide (AL-LAD). BLOTTER, 15 Jul 2016, 2 (1). 23.7 MB. https://doi.org/10.16889/isomerdesign-3
Brandt, SD; Kavanagh, PV; Twamley, B; Westphal, F; Elliott, SP; Wallach, J; Stratford, A; Klein, LM; McCorvy, JD; Nichols, DE; Halberstadt, AL. Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775). Drug Test. Anal., 1 Feb 2018, 10 (2), 310-322. 1.2 MB. https://doi.org/10.1002/dta.2222
Stachulski, AV; Nichols, DE; Scheinmann, F. Stereochemical and NMR reassignment of 6-norlysergic acid diethylamide and 6-nor-6-allyllysergic acid diethylamide. J. Chem. Research (S), 1 Jan 1996, 30–31. 4.0 MB.
EMCDDA. New drugs in Europe, 2015, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2016. 1.0 MB. #28
Nichols, DE. Psychedelics. Pharmacol. Rev., 1 Apr 2016, 68 (2), 264-355. 1.9 MB. https://doi.org/10.1124/pr.115.011478 Updated with published correction to Figure 4 (the α-methyl group was missing in the original)
Halberstadt, AL; Geyer, MA. Effect of hallucinogens on unconditioned behavior. In Behavioral Neurobiology of Psychedelic Drugs; Halberstadt, AL; Vollenweider, FX; Nichols, DE, Eds., Springer, 1 Jan 2017; pp 159-199. 879 kB. https://doi.org/10.1007/7854_2016_466
Nichols, DE. DARK classics in chemical neuroscience: Lysergic acid diethylamide (LSD). ACS Chem. Neurosci., 17 Oct 2018, 9 (10), 2331–2343. 1.1 MB. https://doi.org/10.1021/acschemneuro.8b00043
Jacob, P; Shulgin, AT. Structure-activity relationships of the classic hallucinogens and their analogs. In Hallucinogens: An update. NIDA Research Monograph 146; Lin, GC; Glennon, RA, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office, Washington, DC, ; pp 74–91. 51 kB.
Shulgin, AT. Basic Pharmacology and Effects. In Hallucinogens. A Forensic Drug Handbook; Laing, R; Siegel, JA, Eds., Academic Press, London, ; pp 67–137. 6.3 MB.
Hoffman, AJ. Synthesis and pharmacological evaluation of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. Ph. D. Thesis, Purdue University, 1 Aug 1987. 9.3 MB. #6
Stachulski, AV; Nichols, DE; Scheinmann, F. ChemInform abstract: Stereochemical and NMR reassignment of 6-norlysergic acid diethylamide and 6-nor-6-allyllysergic acid diethylamide. ChemInform, 9 Jul 1996, 27 (28). 31 kB. https://doi.org/10.1002/chin.199628264 #V
Wagmann, L; Richter, LHJ; Kehl, T; Wack, F; Bergstrand, MP; Brandt, SD; Stratford, A; Maurer, HH; Meyer, MR. In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures. Anal. Bioanal. Chem., 7 Jan 2019, n/a. 3.8 MB. https://doi.org/10.1007/s00216-018-1558-9 #23 MS
Heim, R. Synthesis and pharmacology of potent 5-HT2A receptor agonists with N-2-methoxybenzyl partial structure. SC. D. Thesis, Freie Universität, Berlin, 1 Jan 2004. 3.9 MB. #24 In German. MS,NMR,IR
McCorvy, JD. Mapping the binding site of the 5-HT2A receptor using mutagenesis and ligand libraries: Insights into the molecular actions of psychedelics. Ph. D. Thesis, Purdue University, 1 Jan 2012. 3.9 MB. #Allyl-LAD
Halberstadt, AL; Chatha, M; Klein, AK; Wallach, J; Brandt, SD. Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. Neuropharmacology, 1 May 2020, 167 107933. 2.4 MB. https://doi.org/10.1016/j.neuropharm.2019.107933 #AL-LAD
Sexton, JD; Nichols, CD; Hendricks, PS. Population survey data informing the therapeutic potential of classic and novel phenethylamine, tryptamine, and lysergamide psychedelics. Front. Psychiatry, 11 Feb 2020, 10 n/a. 529 kB. https://doi.org/10.3389/fpsyt.2019.00896 #AL-LAD
Tanaka, R; Kawamura, M; Hakamatsuka, T; Kikura-Hanajiri, R. Identification and analysis of LSD derivatives in illegal products as paper sheet. Yakugaku Zasshi, 1 Jan 2020, 140 (5), 739–750. 932 kB. https://doi.org/10.1248/yakushi.19-00230 #4 MS,NMR,UV,other
Tanaka, R; Kawamura, M; Hakamatsuka, T; Kikura-Hanajiri, R. Identification of LSD derivatives, 1cP-LSD, MIPLA and 1B-LSD in illegal products as paper sheet. Yakugaku Zasshi, 1 Nov 2020, 140 (11), 1405–1413. 606 kB. https://doi.org/10.1248/yakushi.20-00124 #8 MS,NMR,UV
Cumming, P; Scheidegger, M; Dornbierer, D; Palner, M; Quednow, BB; Martin-Soelch, C. Molecular and functional imaging studies of psychedelic drug action in animals and humans. Molecules, 1 Jan 2021, 26 (9), 2451. 3.5 MB. https://doi.org/10.3390/molecules26092451 #26
Brandt, SD; Kavanagh, PV; Westphal, F; Pulver, B; Schwelm, HM; Whitelock, K; Stratford, A; Auwärter, V; Halberstadt, AL. Analytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P‐AL‐LAD. Drug Test. Anal., 29 May 2022, n/a. 1.3 MB. https://doi.org/10.1002/dta.3281 #AL-LAD GC,LC,MS,NMR